The test is used in conjunction with the firm's ThyGenX oncogene panel to assess fine needle aspiration samples from indeterminate thyroid nodules.
Researchers and clinicians attempting to select targeted therapies must take sample heterogeneity into account.
Through studies of individuals with an inherited cancer predisposition syndrome, researchers identified germline mutations contributing to sporadic thyroid cancer as well.
The International Thyroid Congress and Annual Meeting of the American Thyroid Association announced studies validating diagnostics tests for several companies.
Under the arrangement, Rosetta would offer physicians the option to have thyroid samples analyzed by FNApath, with indeterminate samples tested with its microRNA assay.
The medical policy update makes the unnamed insurer the first commercial plan to cover ThyraMIR, a microRNA gene expression classifier launched earlier this year.
The company said its revenues rose on increased sales of its Afirma gene expression classifier tests, which benefited from increased insurance coverage.
Aetna is the first major commercial insurer to cover Interpace's ThyGenX and brings the total number of covered lives for it to more than 100 million.
The test differentiates benign thyroid nodules from cancerous ones.
The increased revenues were driven by a 30 percent uptick in Afirma gene expression classifier test volume.
Researchers have sequenced the genome of the depth-dwelling giant squid.
Prosecutors have charged a former Drexel University professor with theft for allegedly spending federal grant money on adult entertainment and other unrelated expenses, according to the Philadelphia Inquirer.
Chris Collins, a former US representative, has been sentenced to more than two years in prison in an insider trading case involving an Australian biotechnology firm, the New York Times reports.
In PNAS this week: Trypanosoma brucei transcripts, estimate of people at risk of inherited retinal disease, and more.